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Background:  Recently, it was reported that statins are associated with lower rates of major adverse cardiovascular events and 
amputations in critical limb ischemia (CLI) patients (pts). However, the impact of statin administration duration on clinical outcomes for pts 
undergoing percutaneous transluminal angioplasty (PTA) due to peripheral arterial disease (PAD) is uncertain.
methods:  A total 286 pts underwent PTA for PAD from Oct 2004 to Feb 2013 from prospective PTA registry was enrolled. Major adverse 
cardiovascular and extremity events (MACEEs) were defined as the composite end-point consisted of cardiac death, myocardial infarction, 
repeat PTA, and amputation. The incidence of MACEEs according to statin duration up to 1-year was evaluated.
results:  The incidences of total MACEEs was in 33.2% (95/286 pts); cardiac death 7 (2.4%), myocardial infarction 3 (1.0%), major and 
minor amputation 56 (19.6%), repeat PTA 46 (16.1%). Not only the univariate logistic regression analysis, but also in multivariate logistic 
regression adjusted by age, gender, hypertension, diabetes, cerebrovascular accident, and chronic renal failure, there was significant risk 
reduction for MACEES in statin use duration 180 and 360 days group, not in statin use duration 30 and 90 days (Table).
conclusion:  In our study, prolonged statin duration at least longer than 6 months was associated with reduced risk of MACEES compared 
with shorter statin duration in pts undergoing PTA for PAD.
 
